Phosphorylation by p38 MAPK as an Alternative Pathway for GSK3β Inactivation

doi:10.1126/science.1156037

Science. Author manuscript; available in PMC 2008 December 8.

Published in final edited form as:

Science. 2008 May 2; 320(5876): 667–670.

doi: 10.1126/science.1156037

PMCID: PMC2597039

NIHMSID: NIHMS67843

Phosphorylation by p38 MAPK as an Alternative Pathway for GSK3β Inactivation

Tina M. Thornton,¹ Gustavo Pedraza-Alva,¹^* Bin Deng,^2,³ C. David Wood,¹ Alexander Aronshtam,¹ James L. Clements,⁴ Guadalupe Sabio,⁵ Roger J. Davis,⁵ Dwight E. Matthews,^1,³ Bradley Doble,⁶ and Mercedes Rincon¹^†

¹Department of Medicine/Immunobiology Program, University of Vermont, Burlington, VT 05405-0068, USA

²Department of Biology, University of Vermont, Burlington, VT 05405-0068, USA

³Department of Chemistry, University of Vermont, Burlington, VT 05405-0068, USA

⁴Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA

⁵Program in Molecular Medicine, University of Massachusetts, Worcester, MA 01605, USA

⁶McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario, L8N 3Z5, Canada

^*Present address: Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, 62210, México.

^†To whom correspondence should be addressed. E-mail: mrincon/at/uvm.edu

The publisher's final edited version of this article is available at Science

See other articles in PMC that cite the published article.

Abstract

Glycogen synthase kinase 3β (GSK3β) is involved in metabolism, neurodegeneration, and cancer. Inhibition of GSK3β activity is the primary mechanism that regulates this widely expressed active kinase. Although the protein kinase Akt inhibits GSK3β by phosphorylation at the N terminus, preventing Akt-mediated phosphorylation does not affect the cell-survival pathway activated through the GSK3β substrate β-catenin. Here, we show that p38 mitogen-activated protein kinase (MAPK) also inactivates GSK3β by direct phosphorylation at its C terminus, and this inactivation can lead to an accumulation of β-catenin. p38 MAPK-mediated phosphorylation of GSK3β occurs primarily in the brain and thymocytes. Activation of β-catenin-mediated signaling through GSK3β inhibition provides a potential mechanism for p38 MAPK-mediated survival in specific tissues.

The p38 mitogen-activated protein kinase (MAPK) is activated through phosphorylation primarily by MAPK kinase 3 (MKK3) and MKK6 in response to cellular stress and cytokines. The p38 MAPK pathway functions in the control of differentiation, the blockade of proliferation, and in the induction of apoptosis (1). It is also activated in response to DNA double-stranded breaks (DSBs) induced by ionizing irradiation or chemotherapeutic drugs, and it participates in the induction of a G₂/M cell-cycle checkpoint (2, 3). p38 MAPK can also promote survival (4-6) by unknown mechanisms. During T cell receptor β (TCRβ) rearrangement, V(D)J recombination-mediated DSBs also activate p38 MAPK in immature thymocytes at the double negative 3 (DN3) stage of development (7, 8). The expression of a constitutively active mutant of MKK6 [MKK6(Glu)] in thymocytes of transgenic mice (MKK6 transgenic mice) activates a p53-mediated G₂/M phase cell-cycle checkpoint (8). Like recombination-activating gene (Rag) deficiency, persistent activation of p38 MAPK interferes with the differentiation of thymocytes beyond the DN3 stage. However, MKK6 transgenic thymocytes (but not Rag^-/- thymocytes) survive and accumulate in vivo (8), suggesting that p38 MAPK may also provide a survival signal. A gene expression profile analysis comparing Rag^-/- and MKK6 DN3 thymocytes revealed that the MKK6 DN3 thymocytes expressed more c-myc and lef (fig. S1) [two transcription factors associated with cell survival (9-11)] than did the Rag^-/- thymocytes. The increased abundance of c-Myc and Lef proteins in the MKK6 transgenic thymocytes, compared with Rag^-/- thymocytes, was confirmed by Western blot analysis (Fig. 1A) (12). Thymocytes from Rag^-/- mice crossed with MKK6 transgenic (Rag^-/- MKK6) mice contained higher amounts of c-Myc and Lef proteins than did Rag^-/- thymocytes, indicating that the activation of p38 MAPK, but not the pre-TCR signals, contributes to the enhanced expression of these transcription factors (Fig. 1B). The c-myc and lef genes are targets of the β-catenin signaling pathway in certain contexts (13, 14). Nuclear accumulation of β-catenin was detected in MKK6 thymocytes, but not in Rag^-/- thymocytes (Fig. 1C). Expression of constitutively active MKK6 in 293T cells was also sufficient to increase the amount of β-catenin protein (Fig. 1D), but this had no effect on β-catenin mRNA (fig. S2).

Fig. 1

Regulation of the β-catenin pathway by p38 MAPK. (A) Western blot showing c-Myc and Lef in whole-cell extracts from Rag^-/- thymocytes (Rag^-/-) and MKK6 thymocytes (MKK6). Actin was examined as a control. (B) Western blot showing c-Myc and Lef (more ...)

Phosphorylation of β-catenin by glycogen synthase kinase 3β (GSK3β) targets β-catenin for ubiquitination and subsequent degradation (15, 16). The best-characterized mechanism for the inactivation of GSK3β is through phosphorylation of its N terminus at Ser⁹ by Akt (17). No increase was observed in the amount of phospho-Ser⁹ GSK3β in MKK6 thymocytes compared with that in Rag^-/- thymocytes (Fig. 2A). Similarly, no increase in phospho-Ser⁹ was observed in 293T cells transfected with constitutively active MKK6 (Fig. 2B). Phosphorylation of Ser⁹ was impaired by Wortmanin, an inhibitor of the PI3K-Akt pathway, but it was not affected by the pharmacological inhibitor of p38 MAPK SB203580 (fig. S3). Thus, p38 MAPK does not appear to regulate the Akt-mediated phosphorylation of GSK3β on Ser⁹. p38 MAPK immunoprecipitated from MKK6 thymocytes or MKK6-transfected 293T cells phosphorylated recombinant catalytically inactive GSK3β in vitro, and this phosphorylation was blocked by the p38 MAPK inhibitor (Fig. 2C). No Akt was detected in p38 MAPK immunoprecipitates, and no p38 MAPK was detected in Akt immunoprecipitates (fig. S4), ruling out the presence of residual AKT associated with p38 MAPK. The depletion of Akt before immunoprecipitating p38 MAPK did not affect the phosphorylation of GSK3β (Fig. 2D). A purified recombinant activated p38 MAPK also phosphorylated GSK3β in vitro, and this phosphorylation was blocked by SB203580 (Fig. 2E). Coimmunoprecipitation analysis showed that p38 MAPK was present in GSK3β immunoprecipitates from MKK6 thymocytes (Fig. 2F) and 293T cells (fig. S5). Thus, p38 MAPK physically associates with and phosphorylates GSK3β at a Ser⁹-independent residue. Although GSK3α and GSK3β are thought to be similarly regulated and can compensate for each other for some functions (18, 19), GSK3α was not phosphorylated by recombinant p38 MAPK in vitro (Fig. 2G).

Fig. 2

Direct phosphorylation of GSK3β by p38 MAPK. (A) Western blot showing phospho-Ser⁹ GSK3β (P-S⁹) and total GSK3β in Rag^-/- and MKK6 thymocytes. (B) Western blot showing P-Ser⁹ GSK3β, GSK3β, phospho-p38 MAPK (P-p38), (more ...)

The MAPK extracellular signal-regulated protein kinase (ERK) phosphorylates Thr⁴³ of GSK3β (20) but does not affect GSK3β activity. Although SerPro or ThrPro motifs recognized by ERK are also recognized by other MAPK groups, p38 MAPK was still able to partially phosphorylate a GSK3β-T⁴³A mutant (Fig. 3A), suggesting the existence of additional phosphorylation sites in GSK3β. Mass spectrometric analysis of recombinant GSK3β phosphorylated in vitro by p38 MAPK revealed two GSK3β phospho-peptides containing phosphorylation within a consensus SerPro or ThrPro motif, a phospho-peptide containing Thr⁴³, and a C-terminal peptide (384 to 403) containing the ThrPro motif at Thr³⁹⁰ (corresponding to Ser³⁸⁹ in mouse GSK3β) (figs. S6 and S7). To confirm Thr³⁹⁰ as a target of p38 MAPK in GSK3β, catalytically inactive GSK3β-T³⁹⁰A and GSK3β-T⁴³A/T³⁹⁰A mutants were used as substrates for p38 MAPK in vitro. Phosphorylation of the GSK3β-T³⁹⁰A mutant by p38 MAPK was partially reduced but not abrogated (Fig. 3B), but phosphorylation of the GSK3β-T⁴³A/T³⁹⁰A mutant was abrogated, indicating that these two residues are probably the targets for p38 MAPK in GSK3β. The T⁴³A mutation (but not the T³⁹⁰A mutation) abrogated phosphorylation of GSK3β by ERK (Fig. 3C). Thus, Thr³⁹⁰ of GSK3β appears to be specifically phosphorylated by p38 MAPK.

Fig. 3

Inhibition of GSK3β by p38 MAPK is mediated by phosphorylation at Thr³⁹⁰. (A) In vitro kinase assays for recombinant p38 MAPK with catalytically inactive GSK3β and GSK3β-T⁴³A mutantas substrates. (B) In vitro kinase assay for recombinant (more ...)

We examined the activity of wild-type (WT) GSK3β and GSK3β-T⁴³A and GSK3β-T³⁹⁰A mutants before or after incubation with p38 MAPK or Akt. p38 MAPK inhibited both WT GSK3β and the GSK3β-T⁴³A mutant (Fig. 3D), but not the GSK3β-T³⁹⁰A mutant (Fig. 3D). Akt inhibited WT GSK3β and the two mutants (Fig. 3D). p38 MAPK did not affect the activity of GSK3α (fig. S8), in which the Thr³⁹⁰ residue from GSK3β is not conserved. Together, these results demonstrate that p38 MAPK-mediated phosphorylation of GSK3β at Thr³⁹⁰ (but not Thr⁴³) is sufficient to inhibit GSK3β activity. A peptide derived from the N terminus of GSK3β containing phospho-Ser⁹ specifically inhibits GSK3β in vitro (21, 22). A phospho-Thr³⁹⁰ peptide also inhibited GSK3β activity, whereas the unphosphorylated-Thr³⁹⁰ peptide did not (Fig. 3E). The phospho-Thr³⁹⁰ peptide inhibited GSK3β activity as efficiently as the phospho-Ser⁹ peptide (Fig. 3F). Thus, phosphorylation at Thr³⁹⁰ by p38 MAPK may cause an inhibition of GSK3β comparable to the phosphorylation of Ser⁹ by Akt.

To demonstrate the phosphorylation of this residue in intact cells and in vivo, we generated a specific antibody (Ab) to a mouse phospho-Ser³⁸⁹ GSK3β peptide. A band corresponding to GSK3β was detected with this Ab in WT and GSK3α^-\- embryonic stem (ES) cells, but not in the GSK3β^-/- ES cells by Western blot analysis (Fig. 4A). This specific band was also present in GSK3β^-/- ES cells transfected with a WT GSK3β, but not with a GSK3β-S³⁸⁹A mutant (Fig. 4B). Phospho-Ser³⁸⁹ GSK3β was detected in mouse GSK3β-transfected 293T cells, but only if active MKK6 was present (Fig. 4C). The presence of the phospho-Ser³⁸⁹ GSK3β in these cells correlated with an increased amount of β-catenin (Fig. 4C), which is indicative of an inhibition of GSK3β activity. Ser³⁸⁹-phosphorylation was also detected in WT GSK3β, but not the GSK3β-S³⁸⁹A mutant after in vitro incubation with activated p38 MAPK (fig. S9). Phosphatase treatment of GSK3β previously incubated with activated p38 MAPK abrogated its recognition by the phospho-Ser³⁸⁹ Ab (fig. S9). Together, these results show the specificity of this Ab for phospho-S³⁸⁹ GSK3β and the phosphorylation of GSK3β at S³⁸⁹ by p38 MAPK in vitro.

Fig. 4

Phosphorylation of endogenous GSK3β by p38 MAPK. (A) Western blot showing the presence of endogenous phospho-Ser³⁸⁹ GSK3β (P-Ser³⁸⁹) in WT, GSK3α^-/-, and GSK3β^-/- ES cells. Total GSK3α, GSK3β, and glyceraldehyde-3-phosphate (more ...)

To determine whether activation of p38 MAPK was required for phosphorylation of GSK3β at Ser³⁸⁹ in intact cells, we treated mouse GSK3β-transfected 293T cells with SB203580. The inhibition of p38 MAPK abrogated the phosphorylation of Ser³⁸⁹ (Fig. 4D). Similarly, treatment with SB203580 inhibited phosphorylation of endogenous GSK3β at Ser³⁸⁹ in WT mouse embryonic fibroblasts (MEFs) and ES cells (Fig. 4E). We also examined phospho-Ser³⁸⁹ abundance in MEFs deficient for the major upstream activators of p38 MAPK, MKK3, and MKK6 (23). Phospho-Ser³⁸⁹ was barely detectable in MKK3^-/-MKK6^-/- MEFs (Fig.4F). In contrast, the amounts of phospho-Ser⁹ were comparable in WT and MKK3^-/-MKK6^-/- MEFs (Fig. 4F). Thus, activation of p38 MAPK appears to be required for the phosphorylation of GSK3β at Ser³⁸⁹. Inhibition of p38 MAPK by either SB203580 (Fig. 4D) or the absence of MKK3 and MKK6 (Fig. 4F) also decreased the amount of β-catenin, consistent with the possibility that p38 MAPK activation is required for repressing GSK3β activity.

We also examined phospho-Ser³⁸⁹ in different mouse tissues. A high amount of phospho-S³⁸⁹ was detected in the brain, and lesser amounts were detected in thymocytes and spleen cells (Fig. 4G). Phospho-Ser³⁸⁹ was not detected in the kidney (Fig. 4G), liver, or heart (fig. S10). Phosphorylation of GSK3β at Ser⁹ was detected in practically all of the examined tissues (Fig. 4G). Analysis of the relative abundance of phospho-S³⁸⁹ and phospho-S⁹ showed a predominance of the former in the brain and thymocytes (Fig. 4G), which correlated with the selective high activation of p38 MAPK in these tissues (fig. S11). Inhibition of p38 MAPK by treating animals with SB203580 reduced the levels of phospho-Ser³⁸⁹ GSK3β in both thymocytes and the brain (Fig. 4H). Analysis of phospho-Ser³⁸⁹ in MKK6 and Rag^-/- thymocytes showed that phospho-S³⁸⁹ GSK3β was present selectively in MKK6 thymocytes (Fig. 4I). Together, these results support our proposal that GSK3β is phosphorylated at S³⁸⁹ in vivo by p38 MAPK and that this alternative regulatory mechanism of GSK3β is tissue-specific.

To date, phosphorylation at Ser⁹ by Akt is the best-characterized mechanism for the inhibition of GSK3β activity. However, knockin mice in which Ser⁹ was replaced by Ala have only a subtle defect related to insulin regulation of glycogen synthase in their skeletal muscle tissue (24), indicating that alternative mechanisms may be involved in the negative regulation of GSK3β for certain functions. We propose that the phosphorylation of GSK3β at S³⁸⁹ by p38 MAPK may be one such mechanism. Conditions that promote the activation of p38 MAPK promote the accumulation of β-catenin in certain scenarios; thus, the activation of the p38 MAPK pathway could be an alternative mechanism to regulate β-catenin/T cell factor signaling (and, potentially, cell survival) through the inactivation of GSK3β.

Supplementary Material

Supplementary

Click here to view.^{(1.9M, pdf)}

Acknowledgments

We thank C. Charland for flow cytometry analysis and cell sorting, T. Hunter and the DNA Sequencing Facility for sequencing, and the Univ. of Vermont Protein Core Facility for peptide synthesis. This work was supported by NIH grants R01 AI051454 and National Center for Research Resources (NCRR) grant P20 RR15557 (M.R.), NCRR grants P20 RR021905 and P20 RR16462 (D.E.M.), and Canada Research Chairs and Canadian Institutes of Health Research grant MOP-85057 (B.D.).

References and Notes

1. Zarubin T, Han J. Cell Res. 2005;15:11. [PubMed]

2. Mikhailov A, Shinohara M, Rieder CL. Cell Cycle. 2005;4:57. [PubMed]

3. She QB, Chen N, Dong Z. J. Biol. Chem. 2000;275:20444. [PubMed]

4. Kurosu T, et al. Apoptosis. 2005;10:1111. [PubMed]

5. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. Cancer Cell. 2007;11:175. [PMC free article] [PubMed]

6. Dmitrieva NI, Bulavin DV, Fornace AJ, Jr, Burg MB. Proc. Natl. Acad. Sci. U.S.A. 2002;99:184. [PubMed]

7. Diehl NL, et al. J. Exp. Med. 2000;191:321. [PMC free article] [PubMed]

8. Pedraza-Alva G, et al. EMBO J. 2006;25:763. [PubMed]

9. Ioannidis V, Beermann F, Clevers H, Held W. Nat. Immunol. 2001;2:691. [PubMed]

10. Gounari F, et al. Nat. Immunol. 2001;2:863. [PubMed]

11. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. Oncogene. 2002;21:3414. [PubMed]

12. Materials and methods are available as supporting material on Science Online.

13. He TC, et al. Science. 1998;281:1509. [PubMed]

14. Filali M, Cheng N, Abbott D, Leontiev V, Engelhardt JF. J. Biol. Chem. 2002;277:33398. [PubMed]

15. Liu C, et al. Cell. 2002;108:837. [PubMed]

16. Salahshor S, Woodgett JR. J. Clin. Pathol. 2005;58:225. [PMC free article] [PubMed]

17. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Nature. 1995;378:785. [PubMed]

18. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. Dev. Cell. 2007;12:957. [PubMed]

19. Doble BW, Woodgett JR. J. Cell Sci. 2003;116:1175. [PMC free article] [PubMed]

20. Ding Q, et al. Mol. Cell. 2005;19:159. [PubMed]

21. Dajani R, et al. Cell. 2001;105:721. [PubMed]

22. Frame S, Cohen P. Biochem. J. 2001;359:1. [PubMed]

23. Brancho D, et al. Genes Dev. 2003;17:1969. [PubMed]

24. McManus EJ, et al. EMBO J. 2005;24:1571. [PubMed]